Exploration on Machanism of Chufeng Yisun Decoction in the Treatment of Corneal Injury Based on Network Pharmacology and Experimental Validation
10.19879/j.cnki.1005-5304.202306415
- VernacularTitle:基于网络药理学及实验验证探讨除风益损汤治疗角膜损伤机制
- Author:
Jiangwei LI
1
,
2
;
Huimei CHEN
;
Wenqing ZHANG
;
Chen OU
;
Xiong CHEN
;
Xiaolei YAO
;
Qinghua PENG
Author Information
1. 湖南中医药大学第一附属医院,湖南 长沙 410007
2. 湖南中医药大学,湖南 长沙 410208
- Keywords:
Chufeng Yisun Decoction;
corneal injury;
autophagy;
inflammation;
network pharmacology
- From:
Chinese Journal of Information on Traditional Chinese Medicine
2024;31(8):23-28
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the mechanism of Chufeng Yisun Decoction in the treatment of corneal injury based on network pharmacology combined with experimental validation.Methods The active components and targets of Chufeng Yisun Decoction were obtained from TCMSP and TCMID databases.Related targets of corneal injury were searched through GeneCards,OMIM,TTD and NCBI-Gene databases.Chinese materia medica-active components-key target network was established.The main active components of Chufeng Yisun Decoction for the treatment of corneal injury were analyzed.The core targets were predicted through PPI network.CCK-8 method was used to screen the optimal concentration of serum containing Chufeng Yisun Decoction for promoting cell growth.Western blot was used to detect autophagy related protein expressions of LC3,LAMP1 and ERK2.Results The main active components of Chufeng Yisun Decoction in the treatment of corneal injury were kaempferol,wogonin,quercetin and paeoniflorin.The core targets were AKT1,TP53,MAPK1,JUN and TNF.The intervention of serum containing Chufeng Yisun Decoction on human corneal fibroblasts could increase the LC3I/LC3II ratio and LAMP1 protein expression,while decrease ERK2 protein expression,which was consistent with the prediction of network pharmacology.Conclusion Chufeng Yisun Decoction treats corneal injury through multiple components,targets and pathways.The mechanism of promoting autophagy therapy for corneal injury is achieved by down-regulating the expression of ERK2 and up-regulating the expression of LC3 and LAMP1.
